Ra Capital Management, a director and more than 10% owner of 89bio Inc. (ETNB), bought common stock worth $49.99 million last ...

(NASDAQ: ETNB) couldn't quite keep pace with the broader stock market on Tuesday. Investors were hesitant to buy shares of ...

SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of ...

SG Americas Securities LLC lifted its holdings in 89bio, Inc. (NASDAQ:ETNB – Free Report) by 18.3% during the fourth quarter, ...

Check Out Our Latest Report on 89bio 89bio Price Performance Shares of ETNB opened at $11.43 on Wednesday. The business’s 50 day moving average price is $7.94 and its two-hundred day moving ...

Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.

It was the best of biotech times, it was the worst of biotech times: One company soars, another stumbles and a third outlines ...

Wolfe Research initiated coverage of 89bio (ETNB) with an Outperform rating and $15 price target. Considering how low the stock is currently ...

89bio announced a public offering of 21.67 million shares at $8.75 each, aiming for $250 million in gross proceeds. The company's reliance on an upsized public offering may indicate a need for ...

Every investor in 89bio, Inc. (NASDAQ:ETNB) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are institutions with 58% ownership. That is, ...

The Inducement Grants have an exercise price per share that is equal to the closing price of 89bio’s common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with ...